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corticosteroids may produce a paradoxical worsening of myasthenia gravis (MG) symptoms within 
the first weeks of treatment. We therefore wanted to assess the hypothesis that a prior infusion of 
intravenous immunoglobulin (IVIG) may have a protective effect. Our primary objectives were to show 
that the coadministration of immunoglobulins and glucocorticoids is safe and effective for controlling 
myasthenic symptoms, and to compare the exacerbation rate with this approach and historical 
practice without IVIG. We recruited 45 patients with generalized MG who required corticosteroids 
for the first time and we gave all IVIG before starting the full doses of prednisone. Monitoring was 
performed with validated scales, questionnaires, and blood tests over a 6-week period. Only 4.4% 
had severe adverse effects related to IVIG and 86.7% improved clinically. Notably, only 2.2% had a 
paradoxical symptom exacerbation in the first weeks of starting prednisone, which was statistically 
lower than the 42% reported in a historical series. We conclude that adjuvant therapy with IVIG when 
starting prednisone for the first time in patients with generalized MG is safe and effective. Given that 
the rate of paradoxical worsening was lower than that previously reported, the addition of iViG may 
have a protective effect against such exacerbations.
Myasthenia gravis (MG) is a rare disease that affects 15–32.89 people per 100,0001–4. Patients with MG clas-
sically present with characteristic symptoms of muscle weakness and fatigability, particularly of the ocular, 
facial, oropharyngeal, limb, and respiratory muscles. The disease is mediated by circulating organ-specific anti-
bodies against skeletal muscle receptors and neuromuscular junction proteins that alter the neuromuscular 
 transmission2, 3.
The first immunosuppressive agents used in the treatment of MG were  corticosteroids5–14. Prednisone is gener-
ally added to anticholinesterase therapy when these alone do not control symptoms. Although there is a lack of 
controlled prospective randomized clinical trials demonstrating its efficacy, several clinical studies have shown 
that daily administration of high-dose corticosteroids can significantly improve  symptoms5, 6, 10, 12, 15–18. However, 
paradoxical exacerbation of MG symptoms by prednisone is a well-described phenomenon, especially in the 
first weeks after starting  treatment7, 19, 20. There is a wide spectrum of severity with prednisone-induced exacer-
bations, with reports ranging from mild cases to deterioration resulting in death due to respiratory  failure9, 20. 
Several hypotheses have been proposed to explain the mechanism of steroid-induced exacerbation. For example, 
antibodies released by degraded lymphocytes may increase cholinesterase activity at the neuromuscular junc-
tion and increase the immune  response9, 18, 20, 21. However, the underlying primary mechanism is not yet clearly 
established and the optimum treatment to achieve maximum effect with minimum side effects is still under 
debate. Some authors have stated that prednisone-induced exacerbations can be avoided by using a regime that 
rapidly escalates to a high dose rather than starting immediately at the target  dose6, 14, 18, but this approach also 
lacks scientific evidence.
Other treatments that have demonstrated efficacy in MG are plasma exchange (PLEX) and intravenous immu-
noglobulins (IVIG)22. PLEX is the comparatively more invasive procedure of the two, requiring trained personnel 
and specific equipment that is not routinely available in all hospitals. IVIG, which was first used for MG in 1984 
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by Gajdos et al.23, has been proven to be effective in several studies. In patients who deteriorated from moderate 
to severe MG, IVIG was superior to placebo at 14 days24. In two trials, IVIG was also shown to be as effective 
as PLEX in controlling MG exacerbations after 14–15 days of  treatment25, 26. Another clinical trial showed that 
a 2 g/kg dose of IVIG was not superior to a 1 g/kg dose when treating  exacerbations27. A retrospective study 
of myasthenic crises determined that patients treated with PLEX had a better ventilatory status and functional 
outcome than those treated with  IVIG28. Another 2016 article in a pediatric population reported that combin-
ing IVIG with prednisone controlled symptoms faster and shortened hospital  stays29. The European Federation 
of the Neurological Societies recommends using IVIG to treat exacerbations or for maintenance in some cases 
of refractory  MG30. Currently there is class A evidence to use IVIG to treat exacerbations of  MG31. In addition, 
some authors recommend IVIG or PLEX before thymectomy to prevent a myasthenic  crisis22, although a recent 
clinical trial did not demonstrate such benefit for  IVIG32. Other authors suggest that treatment with IVIG or 
PLEX can prepare patients who are to receive  immunosuppressives22, 33, and an international consensus on the 
management of MG has stated that treatment with IVIG and PLEX before starting corticosteroids is appropriate 
in an effort to prevent or minimize  exacerbations34. However, there is currently a lack of data to justify the use of 
IVIG before starting immunosuppressive treatment, and as such, its use remains “off-label” (evidence level = 5)31.
In our opinion, IVIG infusions can improve the safety of starting prednisone at maximum doses for the first 
time by reducing the rate of paradoxical steroid-induced exacerbations. Therefore, we aimed to demonstrate 
whether combination treatment with IVIG and prednisone is safe and effective in patients with generalized 
MG receiving remission doses of corticosteroids for the first time. This treatment approach was compared with 
standard treatment in a historical cohort to assess differences in the proportion of patients developing paradoxical 
exacerbation in the first 6 weeks. This has previously been reported by Bae et al. to be 42%.
Subjects and methods
This was a single centre, prospective, monitoring, post-authorization study. In accordance with the Declaration 
of Helsinki, the study was conducted following a protocol approved by the institutional review board of the 
Clinical Research and Clinical Trials Unit (UCICEC) of Bellvitge Biomedical Research Institute (IDIBELL). 
All participants signed an informed written consent form, and investigators maintained participant anonym-
ity by using codes that were stored in a locked area. UCICEC IDIBELL monitored the study regularly. Annual 
reports were sent to two local drug regulatory agencies: the AEMPS (Spanish Agency for Medicines and Health 
Products; code IDI-INM-2016-01) and the Department of Health of the Autonomous Government of Catalonia 
(CCP-INM-2016-01).
We recruited all consecutive patients with generalized MG of grades IIa to V according to the Myasthenia 
Gravis Foundation of America (MGFA) clinical classification  system35 that attended our hospital between April 
2016 and January 2019. Only those meeting the eligibility criteria were included (the inclusion and exclusion 
criteria are specified in Supplementary Table S1). As other international recent  studies32, 36, we also included mild 
generalized MG patients (MGFA class IIA of the MGFA functional class and minimal manifestations category 
of the MGFA Post-Intervention Status at study inclusion).
Patients received one round of IVIG (0.4 g/kg/day for 5 days) and after 7–10 days they were started on full 
therapeutic doses of prednisone (1 mg/kg/day or 0.75 mg/kg/day in patients with comorbidities). The 7–10 day 
wait before starting prednisone was to the exclusion of any patients with highly fluctuating MG who could be 
falsely interpreted as having prednisone exacerbations if recruited (Fig. 1). The treatment received by patients 
was in line with the clinical guidelines for  MG30, 34, 37.
We adopted a policy of close follow-up with a battery of internationally validated scales for MG and with 
standardized quality of life scales and  questionnaires38–44 (see Supplementary appendix). The study visits took 
place before or during IVIG infusion but before starting prednisone (visit 1), as well as at 4 weeks (visit 5) 
and 6 weeks (visit 7) after starting prednisone. In addition, telephone consultations were performed at 1, 2, 3, 
and 5 weeks after starting prednisone (visits 2, 3, 4, and 6) to detect minor paradoxical deteriorations or any 
adverse effects. If patients noticed any deterioration or were concerned, extra visits were made available. We 
also performed blood tests and autoimmune testing, which included anti-acetylcholine receptor antibody and 
anti-striated muscle antibody titres at visits 1, 5, and 7 anti-MuSK antibody titres at visit 1. These blood tests 
were performed at the laboratory of Bellvitge University Hospital (HUB).
At visits 5 and 7, we assessed whether the patient was better, worse, or the same as at visit 1 based on the 
scores from the evaluation scales. Deterioration was defined as a decrease of > 2 points in the Myasthenia Gravis 
Figure 1.  Summary figure of the study with MSS and QMG criteria of significant fluctuations. MSS scale, used 
by Bae et al. and that we have used to measure significant fluctuations as a primary objective.
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Severity Scale (MSS)19, 28 (Supplementary Table 2) or an increase > 3 points in the Quantitative Myasthenia Gravis 
(QMG)38. Improvement in MG was defined as an increase of more than 2 points in the MSS score or a decrease 
greater than 3 points in the QMG score. The patient was categorized as stable if the difference in scores was ≤ 2 
or ≤ 3 on the MSS and QMG scales, respectively (Fig. 1).
All statistical analyses were performed using IBM SPSS version 23.0 (IBM Corp., Armonk, NY, USA). The 
results are presented as numbers and percentages. The Fisher exact test was used to compare categorical variables 
between our series and the historical series published by Bae et al. to assess differences in the development of 
glucocorticoid-induced exacerbations. Statistical significance was set at p < 0.05.
Results
We recruited 47 patients in total. Two patients left the study: one who was misdiagnosed of MG but had progres-
sive bulbar paralysis and one who had worsening of MG secondary to adverse effects to chemotherapy started 
for treatment of thymoma (Fig. 2).
Of the 45 patients included in the analysis, most were men and had an onset of MG after 50 years of age. None 
of the patients had anti-MuSK antibodies and only four were double seronegative. More than half of the patients 
had mild MG (MGFA class IIa or IIb at clinical onset and MM-1 and MM-2 of the MGFA at study inclusion) 
and only two patients presented with MGFA class V. One third of the sample had undergone thymectomy, and 
in two patients, this was because of a thymoma (Table 1).
Regarding the adverse effects of IVIG, more than half of the patients had mild side effects, with mild asymp-
tomatic transaminitis being most common (aspartate transaminase and/or alanine aminotransferase values up 
to 1.2 μkat/L). Only two patients had severe adverse effects: one had a deep venous thrombosis that required 
anticoagulation and one developed a subclinical pulmonary thromboembolism that also required anticoagula-
tion (Table 2). Both of these patients had received the IVIg during hospitalization for myasthenic crisis. No 
patient with mild generalized MG treated with IVIG had severe adverse effects. More than half of the patients 
had side effects attributable to prednisone, with the most frequent being insomnia, irritability, hyperglycaemia, 
and uncontrolled hypertension (Table 2).
Concerning the response to combined therapy with IVIG and prednisone, 39 patients (86.7%) of the sample 
had a clear clinical improvement at week 4 and only one patient (2.2%) had exacerbation of MG symptoms in 
the first weeks of prednisone treatment based on Bae et al.’s criteria with the MSS. Using more sensitive criteria 
to detect significant fluctuations in MG (QMG, MG-Composite scale), we identified two additional patients 
with significant deterioration.
These three cases of paradoxical exacerbation required a second round of IVIG to achieve clinical improve-
ment or stabilization, and they were subsequently maintained on high doses of prednisone. Their conditions 
also improved at subsequent visits. Only one patient did not respond to treatment and remained stable despite 
the prednisone dose and a round of IVIG. Therefore, when analyzing the efficacy of combined therapy, 91.1% of 
patients responded to treatment at 6 weeks (Table 3).
Discussion
Several studies have demonstrated IVIG to be effective in the treatment of  MG24–26, 28. We wanted to utilize the 
potential “protective” effect of IVIG to facilitate the starting of prednisone at full therapeutic doses in patients 
for whom pyridostigmine provided inadequate control of generalized MG. Was also wanted to determine if 
there was a lower rate of paradoxical exacerbations with our approach compared with the rates reported in the 
literature, having found that only 6.7% of our patients developed this exacerbation.
Figure 2.  Diagram showing the patients included in the study.
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There is great disparity in the reported frequency of prednisone-induced exacerbations, with rates ranging 
from 21 to 75% depending on the population  studied6, 9, 18–20. This discrepancy is partly because there is no 
standard definition of exacerbation and because each study uses different definitions and different treatment 
regimens. No previous study has used IVIG as standard prior to starting corticosteroids, but several have focused 
on identifying the predictors of prednisone-induced exacerbation with differing conclusions. Brunner et al. 
suggested that prednisone-induced exacerbation was more severe when the pre-existing MG symptoms were 
more  severe6, and Chung et al. suggested that more severe exacerbations occurred in patients with infiltrating 
 thymoma7. In contrast to these, however, Seybold et al. have maintained that no clinical or epidemiological pre-
dictor is sufficiently  significant18. Indeed, some authors have suggested that prednisone-induced exacerbations 
are merely fluctuations of the underlying  MG10, 12. In the article by Bae et al. the authors identified independent 
predictors of prednisone-induced exacerbation, such as advanced age, predominantly bulbar symptoms, and a 
worse baseline neurological  status19.
Our study population was recruited by consecutive sampling, and as such, was heterogeneous in terms of 
demographic and MG characteristics (type and severity). To compare the incidence of exacerbations in our study 
Table 1.  Demographic and clinical features.
Total 45
Sex
Man, n (%) 30 (66.67)





Mean onset age (years) 65.22 ± 16.31
Age at onset (%)
≥ 50 years 40 (88.9)







IIA, n (%) 10 (22.2)
IIB, n (%) 14 (31.1)
IIIA, n (%) 5 (11.1)
IIIB, n (%) 9 (20)
IV, n (%) 5 (11.1)
V, n (%) 2 (4.4)
Pre-treatment MGFA-PIS category
Minimal manifestations 0 (MM-0) 3 (6.7)
Minimal manifestations-2 (MM-2) 2 (4.4)
Minimal manifestations 3 (MM-3) 7 (15.6)
Exacerbation (E) 33 (73.3)
Pre-treatment MSS (mean ± standard deviation) 12.64 ± 1.64
Thymectomized, n (%) 15 (33.3)
Thymus, n (%)
Thymic hyperplasia 4 (8.9)
Atrophy or thymic remains 9 (20)
Thymoma 2 (4.4)
Chest tomography not suggestive of thymoma 30 (66.7)
Antibodies
AntiRAch, n (%) 41 (91.1)
AntiMusk, n (%) 0 (0)
Double seronegatives 4 (8.9)
Anti striated muscle, n (%) 22 (48.9)
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population with that of the work by Bae et al., we used the same methodology with the inclusion of additional 
evaluation scales to allow for further analysis.
We found that combination treatment with IVIG (2 g/kg/day for 5 days) plus prednisone at a maximum dose 
from the first day was safe, with only two patients (4.4%) experiencing significant adverse effects from IVIG 
and neither requiring hospitalization. Importantly, combined IVIG and prednisone treatment was also safe 
for elderly patients given that 62.2% of our sample were aged > 64 years. We consider this to be key given the 
increase in the number of cases of MG in older people seen in recent  years45. Furthermore, prednisone could be 
started at maximum daily doses from the first day of treatment rather than needing to use the gradually escalat-
ing dose recommended by some  authors18. In turn, this allowed us to achieve a lower total dose to achieve the 
desired effect. Older patients and those with comorbidities (e.g., osteoporosis or diabetes mellitus) prescribed 
lower prednisone doses than indicated in the clinical guideline (i.e., 0.5–0.75 mg/kg/day) also achieved clinically 
significant improvements. Notably, the mean prednisone dose in our study was lower than in the study by Bae 
et al., yet we still had more treatment responders.
We used a battery of scales validated for use in  MG38–44. Both the objective scales for physical examination 
(QMC and MG-composite scale) and the patient-reported scales on treatment response (activities of daily liv-
ing; ADLs) have shown sufficient sensitivity to detect improvement and exacerbation. In contrast, the MSS, 
used by Bae et al. to predict corticosteroid-induced exacerbations, was shown to be less sensitive for detecting 
improvements or exacerbations in our study, where it only detected one of the three exacerbations that occurred. 
In our sample, only 2.2% of patients developed a paradoxical exacerbation according to the criteria used by Bae 
et al., although this percentage was significantly lower (p < 0.00001). However, using the more sensitive QMG 
Table 2.  Advers effects (AE) to intravenous immunoglobulins (IVIg) and prednisone.
AE to IVIG Count (percentage %) Total AE to prednisone Count (percentage %) Total
No 17 (37.8) 17 (37.8) No 20 (44.4) 20 (44.4)
Transaminitis 21 (46.7) 28 (62.2) Insomnia 8 (17.8) 25 (55.6)
Headache 18 (40) Irritability/mood change 6 (13.3)
Flu-like 2 (4.4) High blood pressure 4 (8.9)
Deep vein thrombosis 1 (2.2) Hyperglycemia 4 (8.9)
Varicose phlebitis 1 (2.2) Weight gain 3 (6.7)
Stomack flu 1 (2.2) Edemas 1 (2.2)
Pulmonary embolism 1 (2.2) Other 4 (8.9)
Cutaneous rash 1 (2.2)
Dizziness 1 (2.2)
Table 3.  Comparison between the steroid exacerbated and non-exacerbated myasthenia gravis groups 
between our series and Bae et al. series.
Our series Bae et al.
Exacerbated (n = 1) Non-exacerbated (n = 44) Exacerbated (n = 23) Non-exacerbated (n = 32)
Demographic features
Age (years) 56 66.43 ± 16.38 52.3 ± 13.4 41.1 ± 15.4
Male/female ratio 1 29/15 8/15 12/20
Age at onset (years) 56 65.22 ± 16.32 48.5 ± 14.0 39.8 ± 15.4
Pre-treatment clinical status of MG
Pre-treatment dose of piridostig-
mine (mg) 240 152.14 ± 94.96 259.8 ± 131.9 215.6 ± 115.1
MSS score 12 12.66 ± 1.66 9.4 ± 2.0 12.5 ± 1.6
Functional MG scale score 4 3.22 ± 0.82 4.4 ± 0.6 3.4 ± 0.6
Thymomatous MG (n) 0 2 8 14
Thymectomized MG (n) 0 15 13 17
Laboratory findings
Patients with AChR-Ab (%) 1 90.9% – –
Outcome after use of PDN
Reason for PDN use, bulbar 
symtoms (n) 1 29 23 18
Total PDN dose 100 62.5 ± 15.87 66.7 ± 11.6 62.3 ± 14.5
Dose per body weight (mg/kg) 1 0.9 ± 0.15 1.3 ± 0.3 1.1 ± 0.4
Non-responders (within 6 weeks) 0 1 5 16
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or MG-Composite  scales38, 43, this increased to 6.7% of the patients (still significantly lower than that reported 
by Bae et al.). It should also be noted that two patients in our study underwent thymectomy days after starting 
prednisone and that neither deteriorated clinically despite the added potential for deterioration of MG (surgery 
plus starting prednisone).
Our study has several limitations. The most important of these is that we did not have a parallel control group 
receiving no IVIG before starting prednisone, instead using the same methodology used by Bae et al. to allow 
comparisons with their historic  cohort19. However, that cohort was demographically different from ours and was 
analyzed 10–20 years ago, making strict comparison difficult. Also, we included a lower proportion of patients 
with thymoma than Bae et al. (2 vs 22), and most importantly, our patients had a less severe previous clinical 
status of MG due to being treated as outpatients and required lower doses of pyridostigmine. The high percent-
age of patients with less severe clinical statuses and the low prevalence of thymoma in our sample may bias the 
study toward better outcomes. In addition, we initiated steroids after a 7–10 day wait period after IVIG therapy 
to ensure that we excluded patients with highly fluctuating MG, which could be mistaken for a paradoxical exac-
erbation. Nevertheless, excluding these could have biased our sample toward patients with more stable MG and 
reduced the likelihood of an exacerbation. Another limitation is the small sample size, which should have been 
larger to obtain sufficient statistical power. The results obtained in this study could therefore be an underestima-
tion. There are also two probable systematic assessment biases. The first is that all examinations were performed 
by the same unblinded examiner who may have been biased to wanting to see clinical improvement. To minimize 
this bias, we used standardized scales that have good interobserver and intraobserver correlation. The second 
potential bias is due to the euphoric effect that can occur with prednisone in some patients; this could affect the 
subjective items based on patient perception in the ADL and MG-Composite scales. Despite the clear value of 
telephone visits, having in-person visits would have allowed us to collect data using all physical examination 
scales, rather than just the ADL, with some previous efficacy studies using the QMG 14–15 days after starting 
 IVIG23, 25, 26. Finally, we must acknowledge that the treatment with both IVIG and prednisone is more expensive 
and requires the use of more clinical resources, and that many hospitals may lack the necessary resources.
If we take into account the lower prevalence of paradoxical exacerbations in our study compared with that 
reported by Bae et al., we can propose a hypothesis for future studies: in a patient with generalized MG, pre-
treatment with IVIG before starting de novo prednisone could protect against the known risk of corticosteroid-
induced paradoxical exacerbation. The present study increases the current evidence from class 5 to class 4 for 
the use of IVIG prior to starting corticosteroids and serves as a pilot study for future post-approval, prospective, 
double-blind, randomized, case–control studies to test this association scientifically.
conclusion
In conclusion, combined therapy with IVIG and prednisone in patients with generalized MG is safe and effec-
tive. The rate of prednisone-induced paradoxical exacerbation in our population was lower than that reported 
in previous literature, suggesting that IVIG could have a protective effect against such exacerbations. Further 
prospective research in a larger cohort is needed to confirm this protective effect.
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